Portfolio expansion Harrow is rapidly expanding its retina and ophthalmic portfolio, including BYOOVIZ biosimilar, IHEEZO anesthetic gel, and Verkazia relaunch. This signals cross-selling opportunities with ophthalmology clinics treating retina diseases, corneal conditions, and pediatric VKC patients, as well as potential bundled offerings for clinics seeking comprehensive ophthalmic solutions.

Strategic partnerships Active collaboration with Samsung Bioepis for BYOOVIZ and related biosimilars indicates a channel-ready sales approach with large OEM and distribution partners. Leverage these partnerships to access established ophthalmology networks, drive co-marketing programs, and accelerate product adoption through trusted endorsements.

Clinical evidence push Multiple ASRS presentations and real-world data on SB11 and BYOOVIZ strengthen credibility for physician adoption. Use this on-boarding and training materials to address evidence-based questions, reduce clinician hesitancy, and support formulary and payer negotiations with proven outcomes.

Market momentum Recent acquisitions and the U.S. launch activity, including Verkazia relaunch and TYRVAYA rights acquisition, point to accelerating market presence in dry eye and pediatric therapy segments. Target ophthalmology practices with high patient throughput and payers seeking cost-effective, accessible treatments.

Financial health signal Significant funding and mid-to-large revenue potential position Harrow as a scalable partner for larger purchasing agreements. Explore enterprise-level procurement, regional hospital networks, and group purchasing organization opportunities to secure volume-driven deals and long-term contracts.